{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T05:43:39Z","timestamp":1785908619143,"version":"3.56.0"},"reference-count":14,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T00:00:00Z","timestamp":1785888000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Nelarabine is a purine nucleoside analog used in relapsed or refractory T-cell acute lymphoblastic leukemia (T-ALL) and in up-front pediatric therapy. Although neurologic toxicity is dose-limiting, skeletal muscle toxicity, including rhabdomyolysis, has been reported. Rhabdomyolysis occurred in approximately 2% of nelarabine-treated patients in pediatric COG AALL0434, although the clinical features of these events were not detailed. We report a 7-year-old patient with T-ALL who developed rapidly progressive diffuse myalgia, muscle stiffness, impaired ambulation, dark urine, presumptive myoglobinuria, and a peak creatine kinase (CK) level exceeding 70,000 U\/L shortly after nelarabine administration during consolidation. Nelarabine was discontinued, and aggressive intravenous hydration led to complete clinical and biochemical recovery without acute kidney injury or renal replacement therapy. This case provides a detailed pediatric description of clinically overt nelarabine-associated rhabdomyolysis and emphasizes early recognition, renal-protective management, and CK monitoring in symptomatic patients.<\/jats:p>","DOI":"10.3389\/fonc.2026.1901440","type":"journal-article","created":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T04:43:39Z","timestamp":1785905019000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Nelarabine-associated rhabdomyolysis with severe creatine kinase elevation in a pediatric patient with T-cell acute lymphoblastic leukemia: a case report"],"prefix":"10.3389","volume":"16","author":[{"given":"Fulden","family":"Aycan","sequence":"first","affiliation":[{"name":"Stead Family Department of Pediatrics, Carver College of Medicine, The University of Iowa","place":["Iowa City, IA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna E.","family":"Spykerman","sequence":"additional","affiliation":[{"name":"Stead Family Department of Pediatrics, Carver College of Medicine, The University of Iowa","place":["Iowa City, IA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher Carter","family":"Barnett","sequence":"additional","affiliation":[{"name":"Stead Family Department of Pediatrics, Carver College of Medicine, The University of Iowa","place":["Iowa City, IA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.hoc.2009.07.008","article-title":"Nelarabine for the treatment of patients with relapsed or refractory T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma","volume":"23","author":"DeAngelo","year":"2009","journal-title":"Hematol Oncol Clin North Am"},{"key":"B2","unstructured":"Nelarabine Prescribing Information\n          \n          2025"},{"key":"B3","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1182\/bloodadvances.2023010303","article-title":"Nelarabine: when and how to use in the treatment of T-cell acute lymphoblastic leukemia","volume":"8","author":"Shimony","year":"2024","journal-title":"Blood Adv"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.00256","article-title":"Children\u2019s Oncology Group AALL0434: a phase III randomized clinical trial testing nelarabine in newly diagnosed T-cell acute lymphoblastic leukemia","volume":"38","author":"Dunsmore","year":"2020","journal-title":"J Clin Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.77.7250","article-title":"Improved survival for children and young adults with T-lineage acute lymphoblastic leukemia: results from the Children\u2019s Oncology Group AALL0434 methotrexate randomization","volume":"36","author":"Winter","year":"2018","journal-title":"J Clin Oncol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s40780-022-00247-w","article-title":"Nelarabine-induced rhabdomyolysis in a patient with T-cell acute lymphoblastic leukemia: a case report","volume":"8","author":"Utsumi","year":"2022","journal-title":"J Pharm Health Care Sci"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2020.1791852","article-title":"Nelarabine-related rhabdomyolysis in a patient with T-cell acute lymphoblastic leukemia","volume":"61","author":"Pandey","year":"2020","journal-title":"Leuk Lymphoma"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/825670","article-title":"Nelarabine-associated myotoxicity and rhabdomyolysis","volume":"2015","author":"Haider","year":"2015","journal-title":"Case Rep Hematol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.2174\/1570161113666150130151839","article-title":"Drugs and rhabdomyolysis: from liver to kidney","volume":"13","author":"Barbano","year":"2015","journal-title":"Curr Vasc Pharmacol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1378\/chest.12-2016","article-title":"Rhabdomyolysis","volume":"144","author":"Zimmerman","year":"2013","journal-title":"Chest"},{"key":"B11","article-title":"Rhabdomyolysis","volume-title":"Statpearls","author":"Rout","year":"2026"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2007.09.002","article-title":"Nelarabine: a novel purine antimetabolite antineoplastic agent","volume":"29","author":"Buie","year":"2007","journal-title":"Clin Ther"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo","year":"1981","journal-title":"Clin Pharmacol Ther"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2023.1147033","article-title":"Predictive value of neutrophil gelatinase-associated lipocalin in children with acute kidney injury: a systematic review and meta-analysis","volume":"11","author":"Zou","year":"2023","journal-title":"Front Pediatr"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1901440\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T04:43:56Z","timestamp":1785905036000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1901440\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,5]]},"references-count":14,"alternative-id":["10.3389\/fonc.2026.1901440"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1901440","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,5]]},"article-number":"1901440"}}